Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue: 2023-2024

Historic Current Deferred Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 2 years, with Dec 2024 value amounting to $31.8 million.

  • Kiniksa Pharmaceuticals International's Current Deferred Revenue rose 159.45% to $31.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.8 million, marking a year-over-year increase of 159.45%. This contributed to the annual value of $31.8 million for FY2024, which is 159.45% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Current Deferred Revenue stood at $31.8 million for FY2024, which was up 159.45% from $12.3 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Current Deferred Revenue ranged from a high of $31.8 million in FY2024 and a low of $12.3 million during FY2023.
  • Moreover, its 2-year median value for Current Deferred Revenue was $22.0 million (2023), whereas its average is $22.0 million.
  • Data for Kiniksa Pharmaceuticals International's Current Deferred Revenue shows a peak YoY soared of 159.45% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Kiniksa Pharmaceuticals International's Current Deferred Revenue stood at $12.3 million in 2023, then surged by 159.45% to $31.8 million in 2024.